Theravance Biopharma: Near-Term Game-Changing PDUFAS
Some of the Prohost Portfolio selected companies are having near term PDUFAS which we believe will have a positive outcome. Indeed we expect the FDA approvals to tremendously boost these firms’ values. In Part 1 we chose Halozyme (HALO) and PTC Therapeutics (PTCT). Today, in Part 2 our choice is Theravance Biopharma.
Theravance Biopharma’s (TBPH) upcoming PDUFA is due on August 2, 2020. It is about a supplementary new drug application (sNDA) submitted by GlaxoSmithKline (GSK) regarding the CAPTAIN trial that is investigating the safety and efficacy of Trelegy Ellipta in improving asthmatics’ lung function, quality of life and symptom control over established combination therapies.